成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  2. Cell Cycle/DNA Damage Anti-infection
  3. DNA/RNA Synthesis Influenza Virus SARS-CoV Bacterial
  4. Favipiravir

Favipiravir  (Synonyms: 法匹拉韋; T-705)

目錄號: HY-14768 純度: 99.97%
COA 產(chǎn)品使用指南 技術(shù)支持

Favipiravir (T-705) 是一種病毒 RNA 聚合酶 (RNA polymerase) 抑制劑，可轉(zhuǎn)變?yōu)槠浠钚孕问?Favipiravir-ribofuranosyl-5′-triphosphate (RTP)。Favipiravir-RTP 抑制流感病毒RNA依賴性的RNA聚合酶 (RdRP) 活性，IC50 為 341 nM。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務(wù)

Favipiravir Chemical Structure

Favipiravir Chemical Structure

CAS No. : 259793-96-9

1.  客戶無需承擔(dān)相應(yīng)的運(yùn)輸費用。

2.  同一機(jī)構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機(jī)構(gòu)（單位）一年內(nèi)

     可免費申領(lǐng)三個不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價格 是否有貨 數(shù)量
10 mM * 1 mL in DMSO ￥880
In-stock
5 mg ￥800
In-stock
10 mg ￥1400
In-stock
25 mg ￥2333
In-stock
50 mg ￥3500
In-stock
100 mg ￥4988
In-stock
200 mg   詢價  
500 mg   詢價  

* Please select Quantity before adding items.

Customer Review

Other Forms of Favipiravir:

MCE 顧客使用本產(chǎn)品發(fā)表的 40 篇科研文獻(xiàn)

IF

    Favipiravir purchased from MCE. Usage Cited in: BMC Vet Res. 2019 Sep 2;15(1):316.  [Abstract]

    Comparisons of antiviral effects of T-705 and anti-CDV polyclonal serum. The Vero and DH82 cells were treated with T-705 (156.25 μg/ml), anti-CDV polyclonal serum (1:128) and a combination of T-705 (156.25 μg/ml) and anti-CDV polyclonal serum (1:128) at 0, 12, 24, 36 and 48 h p.i. with CDV-3 and CDV-11 at a MOI of 0.1. The mock groups were treated with DMEM p.i. at the same times. The virus titers in supernatant (b, d, f, h) were determined and compared with the viral titers in mock group. All e

    Favipiravir purchased from MCE. Usage Cited in: BMC Vet Res. 2019 Sep 2;15(1):316.  [Abstract]

    Comparisons of antiviral effects of T-705 and anti-CDV polyclonal serum. The Vero and DH82 cells were treated with T-705 (156.25 μg/ml), anti-CDV polyclonal serum (1:128) and a combination of T-705 (156.25 μg/ml) and anti-CDV polyclonal serum (1:128) at 0, 12, 24, 36 and 48 h p.i. with CDV-3 and CDV-11 at a MOI of 0.1. The mock groups were treated with DMEM p.i. at the same times. Viral replications in cells were detected by IFA and the mean fluorescence percentages (a, c, e, g) were calculated

    • 生物活性

    • 實驗參考方法

    • 純度 & 產(chǎn)品資料

    • 參考文獻(xiàn)

    生物活性

    Favipiravir (T-705) is a potent viral RNA polymerase inhibitor, it is phosphoribosylated by cellular enzymes to its active form, Favipiravir-ribofuranosyl-5′-triphosphate (RTP). Favipiravir-RTP inhibits the influenza viral RNA-dependent RNA polymerase (RdRP) activity with an IC50 of 341 nM.

    IC50 & Target

    IC50: 341 nM (RdRP)[1]
    細(xì)胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    MDCK CC50
    > 100 μM
    Compound: T-705
    Cytotoxicity against MDCK cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
    Cytotoxicity against MDCK cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
    		[PMID: 36764470]
    MDCK CC50
    > 100 μM
    Compound: T-705
    Cytotoxicity against MDCK cells after 3 days by fluorescein diacetate-based fluorimetric analysis
    Cytotoxicity against MDCK cells after 3 days by fluorescein diacetate-based fluorimetric analysis
    		[PMID: 23419738]
    MDCK CC50
    > 250 μM
    Compound: T-705
    Cytotoxicity against MDCK cells assessed as reduction in cell viability after 3 days by formazan-based MTS assay
    Cytotoxicity against MDCK cells assessed as reduction in cell viability after 3 days by formazan-based MTS assay
    		[PMID: 29906392]
    MDCK CC50
    > 250 μM
    Compound: T-705
    Cytotoxicity against HGPRT deficient 6-thioguanine-resistant MDCK cells assessed as reduction in cell viability after 3 days by formazan-based MTS assay
    Cytotoxicity against HGPRT deficient 6-thioguanine-resistant MDCK cells assessed as reduction in cell viability after 3 days by formazan-based MTS assay
    		[PMID: 29906392]
    MDCK CC50
    > 400 μM
    Compound: 1; T-705
    Cytotoxicity against MDCK cells after 10 mins by CellTiter-Glo assay
    Cytotoxicity against MDCK cells after 10 mins by CellTiter-Glo assay
    		[PMID: 27120583]
    MDCK EC50
    0.19 μM
    Compound: T-705
    Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/New York/34/2008(H1N1)) harboring M2 L26I mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysi
    Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/New York/34/2008(H1N1)) harboring M2 L26I mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysi
    		[PMID: 20350949]
    MDCK EC50
    0.38 μM
    Compound: T-705
    Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Ann Arbor/6/1960(H2N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain
    Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Ann Arbor/6/1960(H2N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain
    		[PMID: 20350949]
    MDCK EC50
    0.45 μM
    Compound: T-705
    Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Florida/01/2009(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis
    Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Florida/01/2009(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis
    		[PMID: 20350949]
    MDCK EC50
    0.57 μM
    Compound: T-705
    Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza B virus B/Memphis/20/1996 harboring neuraminidase R152K mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic ana
    Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza B virus B/Memphis/20/1996 harboring neuraminidase R152K mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic ana
    		[PMID: 20350949]
    MDCK EC50
    0.83 μM
    Compound: T-705
    Antiviral activity against adamantane-susceptible zanamivir-, oseltamivir-resistant Influenza A virus (A/Brazil/1633/2008(H1N1)) harboring neuraminidase Q136K mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros
    Antiviral activity against adamantane-susceptible zanamivir-, oseltamivir-resistant Influenza A virus (A/Brazil/1633/2008(H1N1)) harboring neuraminidase Q136K mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros
    		[PMID: 20350949]
    MDCK EC50
    0.83 μM
    Compound: T-705
    Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Swine/South Dakota/03/2008(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet
    Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Swine/South Dakota/03/2008(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet
    		[PMID: 20350949]
    MDCK EC50
    0.83 μM
    Compound: T-705
    Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/California/05/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros
    Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/California/05/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros
    		[PMID: 20350949]
    MDCK EC50
    0.89 μM
    Compound: T-705
    Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/New York/18/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microsco
    Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/New York/18/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microsco
    		[PMID: 20350949]
    MDCK EC50
    0.89 μM
    Compound: T-705
    Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/turkey/Minnesota/833/1980(H4N2)) harboring neuraminidase E119G mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days
    Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/turkey/Minnesota/833/1980(H4N2)) harboring neuraminidase E119G mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days
    		[PMID: 20350949]
    MDCK EC50
    0.96 μM
    Compound: T-705
    Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/turkey/Minnesota/833/1980(H4N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet
    Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/turkey/Minnesota/833/1980(H4N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet
    		[PMID: 20350949]
    MDCK EC50
    1.21 μM
    Compound: T-705
    Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Bethesda/956/2006(H3N2)) harboring neuraminidase R292K mutant and M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication af
    Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Bethesda/956/2006(H3N2)) harboring neuraminidase R292K mutant and M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication af
    		[PMID: 20350949]
    MDCK EC50
    1.21 μM
    Compound: T-705
    Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza B virus B/Memphis/20/1996 infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain
    Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza B virus B/Memphis/20/1996 infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain
    		[PMID: 20350949]
    MDCK EC50
    1.21 μM
    Compound: T-705
    Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/Mexico/4604/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microsco
    Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/Mexico/4604/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microsco
    		[PMID: 20350949]
    MDCK EC50
    1.27 μM
    Compound: T-705
    Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/chicken/Vietnam/NCVD103/2007 clade 2.3.4 (H5N1)) harboring neuraminidase I222T mutant infected in MDCK cells assessed as inhibition of viral replication after
    Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/chicken/Vietnam/NCVD103/2007 clade 2.3.4 (H5N1)) harboring neuraminidase I222T mutant infected in MDCK cells assessed as inhibition of viral replication after
    		[PMID: 20350949]
    MDCK EC50
    1.32 μM
    Compound: T-705
    Antiviral activity against Influenza B virus (B/Brisbane/60/2008) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis
    Antiviral activity against Influenza B virus (B/Brisbane/60/2008) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis
    		[PMID: 23419738]
    MDCK EC50
    1.341 μM
    Compound: T-705
    Antiviral activity against adamantane-, oseltamivir-, zanamivir-resistant Influenza A virus (A/Vietnam/HN30408/2005 N294S clade 1 (H5N1)) harboring M2 L26I, S31N mutant and neuraminidase N294S mutant infected in MDCK cells assessed as inhibition of viral
    Antiviral activity against adamantane-, oseltamivir-, zanamivir-resistant Influenza A virus (A/Vietnam/HN30408/2005 N294S clade 1 (H5N1)) harboring M2 L26I, S31N mutant and neuraminidase N294S mutant infected in MDCK cells assessed as inhibition of viral
    		[PMID: 20350949]
    MDCK EC50
    1.4 μM
    Compound: T-705
    Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza B virus (B/Rochester/01/2001) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain
    Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza B virus (B/Rochester/01/2001) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain
    		[PMID: 20350949]
    MDCK EC50
    1.4 μM
    Compound: T-705
    Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/California/07/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros
    Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/California/07/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros
    		[PMID: 20350949]
    MDCK EC50
    1.46 μM
    Compound: T-705
    Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Georgia/17/2006(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain
    Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Georgia/17/2006(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain
    		[PMID: 20350949]
    MDCK EC50
    1.53 μM
    Compound: T-705
    Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/turkey/VA/4529/2002 (H7N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain
    Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/turkey/VA/4529/2002 (H7N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain
    		[PMID: 20350949]
    MDCK EC50
    1.59 μM
    Compound: T-705
    Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/Florida/21/2008(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microsc
    Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/Florida/21/2008(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microsc
    		[PMID: 20350949]
    MDCK EC50
    1.59 μM
    Compound: T-705
    Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/duck/Vietnam/NCVD93/2007 clade 2.3.4 (H5N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using cry
    Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/duck/Vietnam/NCVD93/2007 clade 2.3.4 (H5N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using cry
    		[PMID: 20350949]
    MDCK EC50
    1.72 μM
    Compound: T-705
    Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza B virus (B/Rochester/01/2001) harboring neuraminidase D198N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic
    Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza B virus (B/Rochester/01/2001) harboring neuraminidase D198N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic
    		[PMID: 20350949]
    MDCK EC50
    1.85 μM
    Compound: T-705
    Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Brazil/1067/2008(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain
    Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Brazil/1067/2008(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain
    		[PMID: 20350949]
    MDCK EC50
    1.93 μM
    Compound: T-705
    Antiviral activity against Influenza B virus (B/Lee/40) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis
    Antiviral activity against Influenza B virus (B/Lee/40) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis
    		[PMID: 23419738]
    MDCK EC50
    1.94 μM
    Compound: T-705
    Antiviral activity against Influenza B virus (B/Panama/45/1990) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis
    Antiviral activity against Influenza B virus (B/Panama/45/1990) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis
    		[PMID: 23419738]
    MDCK EC50
    1.97 μM
    Compound: T-705
    Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/California/04/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros
    Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/California/04/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros
    		[PMID: 20350949]
    MDCK EC50
    10.2 μM
    Compound: T-705
    Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/New York/107/2003(H7N2)) harboring M2 V28A, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic
    Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/New York/107/2003(H7N2)) harboring M2 V28A, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic
    		[PMID: 20350949]
    MDCK EC50
    11.5 μM
    Compound: T-705
    Inhibition of Influenza A virus (A/gull/Pennsylvania/4175/83 (H5N1)) replication in MDCK cells by neutral red uptake assay
    Inhibition of Influenza A virus (A/gull/Pennsylvania/4175/83 (H5N1)) replication in MDCK cells by neutral red uptake assay
    		[PMID: 17194832]
    MDCK EC50
    12.1 μM
    Compound: T-705
    Inhibition of viral replication of influenza A virus (A/Vietnam/1203/2004 (H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay
    Inhibition of viral replication of influenza A virus (A/Vietnam/1203/2004 (H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay
    		[PMID: 17194832]
    MDCK EC50
    2.23 μM
    Compound: T-705
    Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/swine/Michigan/09/2007 (H1N2)) harboring M2 V27I, V28D mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic a
    Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/swine/Michigan/09/2007 (H1N2)) harboring M2 V27I, V28D mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic a
    		[PMID: 20350949]
    MDCK EC50
    2.48 μM
    Compound: T-705
    Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Ecuador/5179/2008(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain
    Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Ecuador/5179/2008(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain
    		[PMID: 20350949]
    MDCK EC50
    2.55 μM
    Compound: T-705
    Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/Georgia/20/2006(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microsc
    Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/Georgia/20/2006(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microsc
    		[PMID: 20350949]
    MDCK EC50
    2.6 μM
    Compound: T-705
    Inhibition of viral replication of influenza A virus (A/Hong Kong/213/03(H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay
    Inhibition of viral replication of influenza A virus (A/Hong Kong/213/03(H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay
    		[PMID: 17194832]
    MDCK EC50
    2.7 μM
    Compound: 1; T-705
    Antiviral activity against Influenza A virus A/WSN/33(H1N1) infected in MDCK cells assessed as inhibition of neuraminidase activity using 2'-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid substrate pretreated with cells for 24 hrs followed by vira
    Antiviral activity against Influenza A virus A/WSN/33(H1N1) infected in MDCK cells assessed as inhibition of neuraminidase activity using 2'-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid substrate pretreated with cells for 24 hrs followed by vira
    		[PMID: 27120583]
    MDCK EC50
    2.84 μM
    Compound: T-705
    Antiviral activity against Influenza B virus (B/Taiwan/2/62) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis
    Antiviral activity against Influenza B virus (B/Taiwan/2/62) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis
    		[PMID: 23419738]
    MDCK EC50
    2.87 μM
    Compound: T-705
    Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Wisconsin/16/2008(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros
    Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Wisconsin/16/2008(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros
    		[PMID: 20350949]
    MDCK EC50
    2.93 μM
    Compound: T-705
    Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Luhansk/18/2008(H1N1)) harboring neuraminidase H274Y mutant and M2 G34E mutant infected in MDCK cells assessed as inhibition of viral replication afte
    Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Luhansk/18/2008(H1N1)) harboring neuraminidase H274Y mutant and M2 G34E mutant infected in MDCK cells assessed as inhibition of viral replication afte
    		[PMID: 20350949]
    MDCK EC50
    2.93 μM
    Compound: T-705
    Antiviral activity against adamantane-, oseltamivir-, zanamivir-resistant Influenza A virus (A/Idaho/01/2009(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysi
    Antiviral activity against adamantane-, oseltamivir-, zanamivir-resistant Influenza A virus (A/Idaho/01/2009(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysi
    		[PMID: 20350949]
    MDCK EC50
    22.48 μM
    Compound: T-705
    Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/pdm/Illinois/10/2009(H1N1)) harboring M2 V28I, S31N mutant and neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral repli
    Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/pdm/Illinois/10/2009(H1N1)) harboring M2 V28I, S31N mutant and neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral repli
    		[PMID: 20350949]
    MDCK EC50
    3 μM
    Compound: T-705
    Antiviral activity against adamantane-, oseltamivir-, zanamivir-resistant Influenza B virus (B/Illinois/03/2008) harboring neuraminidase E119A mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis u
    Antiviral activity against adamantane-, oseltamivir-, zanamivir-resistant Influenza B virus (B/Illinois/03/2008) harboring neuraminidase E119A mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis u
    		[PMID: 20350949]
    MDCK EC50
    3.25 μM
    Compound: T-705
    Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/Washington/10/2008(H1N1)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic anal
    Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/Washington/10/2008(H1N1)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic anal
    		[PMID: 20350949]
    MDCK EC50
    3.38 μM
    Compound: T-705
    Antiviral activity against adamantane-susceptible zanamivir-, oseltamivir-resistant Influenza A virus (A/duck/Vietnam/NCVD94/2007 clade 2.3.4 (H5N1)) harboring neuraminidase I117V mutant infected in MDCK cells assessed as inhibition of viral replication a
    Antiviral activity against adamantane-susceptible zanamivir-, oseltamivir-resistant Influenza A virus (A/duck/Vietnam/NCVD94/2007 clade 2.3.4 (H5N1)) harboring neuraminidase I117V mutant infected in MDCK cells assessed as inhibition of viral replication a
    		[PMID: 20350949]
    MDCK EC50
    3.63 μM
    Compound: T-705
    Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/California/27/2007(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain
    Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/California/27/2007(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain
    		[PMID: 20350949]
    MDCK EC50
    3.95 μM
    Compound: T-705
    Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Texas/12/2007 (clone)(H3N2)) harboring neuraminidase E119I mutant and harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral
    Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Texas/12/2007 (clone)(H3N2)) harboring neuraminidase E119I mutant and harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral
    		[PMID: 20350949]
    MDCK EC50
    4.01 μM
    Compound: T-705
    Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza B virus (B/Illinois/47/2005) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain
    Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza B virus (B/Illinois/47/2005) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain
    		[PMID: 20350949]
    MDCK EC50
    4.08 μM
    Compound: T-705
    Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/New Hampshire/01/2009(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic an
    Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/New Hampshire/01/2009(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic an
    		[PMID: 20350949]
    MDCK EC50
    4.14 μM
    Compound: T-705
    Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Vietnam/HN30408/2005 H274Y clade 1 (H5N1)) harboring M2 L26I, S31N mutant and neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition
    Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Vietnam/HN30408/2005 H274Y clade 1 (H5N1)) harboring M2 L26I, S31N mutant and neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition
    		[PMID: 20350949]
    MDCK EC50
    4.2 μM
    Compound: T-705
    Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Massachusetts/03/2009(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic an
    Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Massachusetts/03/2009(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic an
    		[PMID: 20350949]
    MDCK EC50
    4.46 μM
    Compound: T-705
    Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Washington/01/2007(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analy
    Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Washington/01/2007(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analy
    		[PMID: 20350949]
    MDCK EC50
    4.5 μM
    Compound: T-705
    Inhibition of influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) replication in MDCK cells by neutral red uptake assay
    Inhibition of influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) replication in MDCK cells by neutral red uptake assay
    		[PMID: 17194832]
    MDCK EC50
    4.52 μM
    Compound: T-705
    Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Swine/Texas/14/2008 (H1N1)) harboring M2 V27T, V28D mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic anal
    Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Swine/Texas/14/2008 (H1N1)) harboring M2 V27T, V28D mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic anal
    		[PMID: 20350949]
    MDCK EC50
    4.7 μM
    Compound: T-705
    Antiviral activity against adamantane-susceptible zanamivir-, oseltamivir-resistant Influenza A virus (A/Santiago/5248/2008(H1N1)) harboring neuraminidase D198E mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micr
    Antiviral activity against adamantane-susceptible zanamivir-, oseltamivir-resistant Influenza A virus (A/Santiago/5248/2008(H1N1)) harboring neuraminidase D198E mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micr
    		[PMID: 20350949]
    MDCK EC50
    4.71 μM
    Compound: T-705
    Antiviral activity against Influenza A virus (A/Hong kong/8/1968(H2N3)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis
    Antiviral activity against Influenza A virus (A/Hong kong/8/1968(H2N3)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis
    		[PMID: 23419738]
    MDCK EC50
    4.9 μM
    Compound: T-705
    Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/New Jersey/15/2007(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micr
    Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/New Jersey/15/2007(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micr
    		[PMID: 20350949]
    MDCK EC50
    5.03 μM
    Compound: T-705
    Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/North Carolina/02/ 2009(H1N1)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic
    Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/North Carolina/02/ 2009(H1N1)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic
    		[PMID: 20350949]
    MDCK EC50
    5.03 μM
    Compound: T-705
    Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza B virus (B/Michigan/20/2005) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic
    Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza B virus (B/Michigan/20/2005) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic
    		[PMID: 20350949]
    MDCK EC50
    5.22 μM
    Compound: T-705
    Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Texas/12/2007 (clone)(H3N2)) harboring neuraminidase E119V mutant and harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral
    Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Texas/12/2007 (clone)(H3N2)) harboring neuraminidase E119V mutant and harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral
    		[PMID: 20350949]
    MDCK EC50
    5.22 μM
    Compound: T-705
    Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Vietnam/1203/2004 clade 1 (H5N1)) harboring M2 L26I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by mic
    Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Vietnam/1203/2004 clade 1 (H5N1)) harboring M2 L26I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by mic
    		[PMID: 20350949]
    MDCK EC50
    5.3 μM
    Compound: T-705
    Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza B virus (B/New York/22/2008) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain
    Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza B virus (B/New York/22/2008) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain
    		[PMID: 20350949]
    MDCK EC50
    5.41 μM
    Compound: T-705
    Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Wuhan/395/1995-like (H3N2)) harboring neuraminidase E119V mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by mi
    Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Wuhan/395/1995-like (H3N2)) harboring neuraminidase E119V mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by mi
    		[PMID: 20350949]
    MDCK EC50
    5.99 μM
    Compound: T-705
    Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Wuhan/395/1995-like (H3N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal viole
    Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Wuhan/395/1995-like (H3N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal viole
    		[PMID: 20350949]
    MDCK EC50
    6.62 μM
    Compound: T-705
    Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/pdm/Washington/29/2009 (H1N1)) harboring M2 V28I, S31N mutant and neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral re
    Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/pdm/Washington/29/2009 (H1N1)) harboring M2 V28I, S31N mutant and neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral re
    		[PMID: 20350949]
    MDCK EC50
    6.95 μM
    Compound: T-705
    Antiviral activity against Influenza A virus (A/Taiwan/1/1986(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis
    Antiviral activity against Influenza A virus (A/Taiwan/1/1986(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis
    		[PMID: 23419738]
    Vero CC50
    > 6257 μM
    Compound: T-705
    Cytotoxicity against african green monkey Vero 76 cells assessed as cell viability after 3 to 5 days
    Cytotoxicity against african green monkey Vero 76 cells assessed as cell viability after 3 to 5 days
    		[PMID: 17606691]
    Vero CC50
    > 6370 μM
    Compound: T-705
    Cytotoxicity against African green monkey Vero cells by luciferase-based cell viability assay
    Cytotoxicity against African green monkey Vero cells by luciferase-based cell viability assay
    		[PMID: 18955536]
    Vero CC50
    1114 μM
    Compound: T-705
    Cytotoxicity against african green monkey Vero cells after 7 to 8 days by neutral-red dye uptake assay
    Cytotoxicity against african green monkey Vero cells after 7 to 8 days by neutral-red dye uptake assay
    		[PMID: 17606691]
    Vero EC50
    180 μM
    Compound: T-705
    Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as inhibition of virus induced cytopathic effect by microscopic analysis
    Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as inhibition of virus induced cytopathic effect by microscopic analysis
    		[PMID: 18955536]
    Vero EC50
    270 μM
    Compound: T-705
    Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as inhibition of virus induced cytopathic effect after 2 hrs by NR dye uptake assay
    Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as inhibition of virus induced cytopathic effect after 2 hrs by NR dye uptake assay
    		[PMID: 18955536]
    Vero EC50
    270 μM
    Compound: T-705
    Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as inhibition of virus induced cytopathic effect by luciferase reporter gene assay
    Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as inhibition of virus induced cytopathic effect by luciferase reporter gene assay
    		[PMID: 18955536]
    Vero EC50
    5 μM
    Compound: T-705
    Antiviral activity against Junin virus Candid-1 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days
    Antiviral activity against Junin virus Candid-1 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days
    		[PMID: 17606691]
    Vero EC50
    6 μM
    Compound: T-705
    Antiviral activity against Pichinde virus An 4763 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days
    Antiviral activity against Pichinde virus An 4763 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days
    		[PMID: 17606691]
    Vero EC50
    6 μM
    Compound: T-705
    Antiviral activity against Tacaribe virus TRVL11573 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days
    Antiviral activity against Tacaribe virus TRVL11573 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days
    		[PMID: 17606691]
    Vero C1008 CC50
    > 400 μM
    Compound: T-705
    Cytotoxicity against African green monkey Vero E6 cells assessed as cell growth inhibition incubated for 48 hrs by CCK8 assay
    Cytotoxicity against African green monkey Vero E6 cells assessed as cell growth inhibition incubated for 48 hrs by CCK8 assay
    		[PMID: 32771797]
    Vero C1008 CC50
    > 400 μM
    Compound: Favipiravir
    Cytotoxicity against African green monkey Vero E6 cells assessed as reduction of cell viability measured after 48 hrs by CCK-8 assay
    Cytotoxicity against African green monkey Vero E6 cells assessed as reduction of cell viability measured after 48 hrs by CCK-8 assay
    		[PMID: 32563814]
    Vero C1008 CC50
    > 400 μM
    Compound: 55
    Cytotoxicity against African green monkey Vero E6 cells by CCK-8 assay
    Cytotoxicity against African green monkey Vero E6 cells by CCK-8 assay
    		[PMID: 33486200]
    Vero C1008 CC50
    > 400 μM
    Compound: 4; FPV
    Cytotoxicity against African green monkey Vero E6 cells by the CCK8 assay
    Cytotoxicity against African green monkey Vero E6 cells by the CCK8 assay
    		[PMID: 32845145]
    Vero C1008 CC50
    > 400 μM
    Compound: Favipiravir
    Cytotoxicity against African green monkey Vero E6 cells by CCK8 assay
    Cytotoxicity against African green monkey Vero E6 cells by CCK8 assay
    		[PMID: 32511912]
    體外研究
    (In Vitro)

    Favipiravir (T 705) 是一種抗病毒藥物，可選擇性抑制流感病毒的 RNA 依賴性 RNA 聚合酶。Favipiravir (T 705) 是一種新型抗病毒化合物，可選擇性地有效抑制流感和許多其他 RNA 病毒的 RNA 依賴性 RNA 聚合酶 (RdRP)。Favipiravir-RTP 不會抑制人類 DNA 聚合酶 α、β 或 γ，IC50>1 mM。人類 RNA 聚合酶 II 的 IC50 為 905 μM；因此，F(xiàn)avipiravir 對流感病毒 RdRP 的選擇性是后者的 2,650 倍，這與對宿主細(xì)胞 DNA 和 RNA 合成缺乏抑制相一致[1]。
    Favipiravir (T 705) 是一種前藥，其細(xì)胞毒性預(yù)計與細(xì)胞系有關(guān)。Favipiravir 以劑量依賴性方式抑制 MNV 誘導(dǎo)的 CPE（EC50：250±11 μM）和細(xì)胞培養(yǎng)中的 MNV RNA 合成（EC50：124±42 μM）。盡管抗病毒活性相當(dāng)?shù)?，?Favipiravir (T 705) 能夠在 100 μg/mL 濃度下完全抑制諾如病毒復(fù)制，該濃度對宿主細(xì)胞幾乎沒有或沒有不良影響（細(xì)胞存活率 >80%）[2]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    體內(nèi)研究
    (In Vivo)

    與安慰劑相比，F(xiàn)avipiravir (T 705)（30 mg/kg/天，口服）可提高存活率。Favipiravir (T 705) 還可在劑量為 33 mg/kg/天或更高時顯著保護(hù)小鼠免受 A/Duck/MN/1525/81(H5N1) 病毒的侵害，無論每日服用多少次。每天服用 4 次，所有小鼠均能存活[1]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial
    分子量

    157.10

    Formula

    C5H4FN3O2
    CAS 號
    性狀

    固體

    顏色

    White to light yellow

    中文名稱

    法匹拉韋
    運(yùn)輸條件

    Room temperature in continental US; may vary elsewhere.
    儲存方式
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 2 years
    -20°C 1 year
    溶解性數(shù)據(jù)
    細(xì)胞實驗： 

    DMSO 中的溶解度 : 100 mg/mL (636.54 mM; 超聲助溶; 吸濕的 DMSO 對產(chǎn)品的溶解度有顯著影響，請使用新開封的 DMSO)

    H2O 中的溶解度 : 6.25 mg/mL (39.78 mM; 超聲助溶)

    配制儲備液
    濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
    1 mM 6.3654 mL 31.8269 mL 63.6537 mL
    5 mM 1.2731 mL 6.3654 mL 12.7307 mL
    查看完整儲備液配制表

    * 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
    儲備液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C儲存時，請在2年內(nèi)使用， -20°C儲存時，請在1年內(nèi)使用。

    * 備注：如您選擇水作為儲備液，請稀釋至工作液后，再用 0.22 μm 的濾膜過濾除菌后使用。

    • 摩爾計算器

    • 稀釋計算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質(zhì)量
    =
    濃度
    ×
    體積
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    濃度 (start)

    C1

    ×
    體積 (start)

    V1

    =
    濃度 (final)

    C2

    ×
    體積 (final)

    V2

    動物實驗：

    請根據(jù)您的 實驗動物和給藥方式 選擇適當(dāng)?shù)娜芙夥桨浮?

    以下溶解方案都請先按照 In Vitro 方式配制澄清的儲備液，再依次添加助溶劑：
    ——為保證實驗結(jié)果的可靠性，澄清的儲備液可以根據(jù)儲存條件，適當(dāng)保存；體內(nèi)實驗的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
    以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

    • 方案 一

      請依序添加每種溶劑： 10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (15.91 mM); 澄清溶液

      此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液。

      以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL。

      生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
    • 方案 二

      請依序添加每種溶劑： 10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (15.91 mM); 澄清溶液

      此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液。

      以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液 中，混合均勻。

      2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。

    以下溶解方案，請直接配制工作液。建議現(xiàn)用現(xiàn)配，在短期內(nèi)盡快用完。 以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比； 如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶。

    • 方案 一

      請依序添加每種溶劑： PBS

      Solubility: 4.55 mg/mL (28.96 mM); 澄清溶液; 超聲助溶

    動物溶解方案計算器
    請輸入動物實驗的基本信息：

    給藥劑量

    mg/kg

    動物的平均體重

    g

    每只動物的給藥體積

    μL

    動物數(shù)量

    只
    由于實驗過程有損耗，建議您多配一只動物的量
    請輸入您的動物體內(nèi)配方組成：
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    如果您的動物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。
    方案所需 助溶劑 包括：DMSO， ，均可在 MCE 網(wǎng)站選購。 ，Tween 80，均可在 MCE 網(wǎng)站選購。
    計算結(jié)果
    工作液所需濃度 : mg/mL
    儲備液配制方法 : mg 藥物溶于 μL  DMSO（母液濃度為 mg/mL）。
    您所需的儲備液濃度超過該產(chǎn)品的實測溶解度，以下方案僅供參考，如有需要，請與 MCE 中國技術(shù)支持聯(lián)系。
    動物實驗體內(nèi)工作液的配制方法 : 取 μL DMSO 儲備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。
    連續(xù)給藥周期超過半月以上，請謹(jǐn)慎選擇該方案。
    請確保第一步儲備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱 （超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。
    純度 & 產(chǎn)品資料

    純度: 99.97%

    參考文獻(xiàn)
    Cell Assay
    [2]

    The antiviral activity of Favipiravir (T 705) is determined using an MTS-based CPE reduction assay in the MNV/RAW 264.7 cell line. To this end, RAW 264.7 cells are seeded (1×104 cells/well) in 96-well plates and infected with MNV at an MOI of 0,001 in the presence (or absence) of a dilution series of Favipiravir (T 705) (3.13-200 μg/mL). Following 3 days of incubation, i.e. until complete CPE is observed in infected untreated cells, cell culture supernatants are collected for quantification of viral RNA load by quantitative RT-PCR (qRT-PCR). For the MTS reduction assay an MTS/Phenazine methosulphate (PMS) stock solution (2 mg/mL MTS and 46 g/mL PMS in PBS at pH 6-6.5) is diluted 1/20 in MEM. To each well, 75 μL of MTS/PMS solution is added and the optical density (OD) is read at 498 nm 2 h later. The % CPE reduction is calculated as [(ODtreated)MNW?ODVC]/[ODCC-ODVC]×100, where ODCC represents the OD of the uninfected untreated cells, whereas ODVC and (ODtreated)CC represent the OD of infected untreated cells and virus-infected cells treated with a compound concentration, respectively. The EC50 is defined as the compound concentration that protected 50% of cells from virus-induced CPE. Adverse effects of the molecule on the host cell are also assessed by means of the MTS-method, by exposing uninfected cells to the same concentrations of Favipiravir for 3 days. The % cell viability is calculated as (ODtreated/ODCC)×100, where ODCC is the OD of uninfected untreated cells and ODtreated are uninfected cells treated with compound. The CC50 is defined as the compound concentration that reduces the number of viable cells by 50%. The selectivity index (SI) is calculated as CC50/EC50[2].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Animal Administration
    [1]

    Mice[1]
    Favipiravir (T 705) has also been shown to protect mice against lethal infection by a variety of influenza virus strains. When Favipiravir is orally administered 2 or 4 times a day for 5 days in mice infected with lethal doses of influenza virus A/Victoria/3/75(H3N2), A/Osaka/5/70(H3N2) or A/Duck/MN/1525/81(H5N1).

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    參考文獻(xiàn)

    完整儲備液配制表

    * 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
    儲備液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C儲存時，請在2年內(nèi)使用， -20°C儲存時，請在1年內(nèi)使用。

    可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
    H2O / DMSO 1 mM 6.3654 mL 31.8269 mL 63.6537 mL 159.1343 mL
    5 mM 1.2731 mL 6.3654 mL 12.7307 mL 31.8269 mL
    10 mM 0.6365 mL 3.1827 mL 6.3654 mL 15.9134 mL
    15 mM 0.4244 mL 2.1218 mL 4.2436 mL 10.6090 mL
    20 mM 0.3183 mL 1.5913 mL 3.1827 mL 7.9567 mL
    25 mM 0.2546 mL 1.2731 mL 2.5461 mL 6.3654 mL
    30 mM 0.2122 mL 1.0609 mL 2.1218 mL 5.3045 mL
    DMSO 40 mM 0.1591 mL 0.7957 mL 1.5913 mL 3.9784 mL
    50 mM 0.1273 mL 0.6365 mL 1.2731 mL 3.1827 mL
    60 mM 0.1061 mL 0.5304 mL 1.0609 mL 2.6522 mL
    80 mM 0.0796 mL 0.3978 mL 0.7957 mL 1.9892 mL
    100 mM 0.0637 mL 0.3183 mL 0.6365 mL 1.5913 mL

    * 備注：如您選擇水作為儲備液，請稀釋至工作液后，再用 0.22 μm 的濾膜過濾除菌后使用。

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的產(chǎn)品:

    Your information is safe with us. * Required Fields.

       產(chǎn)品名稱：

    		  

    * 需求量：

    * 客戶姓名：

    		 

    * Email：

    * 電話：

    		 

    * 公司或機(jī)構(gòu)名稱：

       留言給我們：

    Bulk Inquiry

    Inquiry Information

    產(chǎn)品名稱：
    Favipiravir
    目錄號：
    HY-14768
    需求量：